Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Profit After Tax (2016 - 2025)

Seres Therapeutics' Profit After Tax history spans 11 years, with the latest figure at $8.2 million for Q3 2025.

  • For Q3 2025, Profit After Tax fell 90.76% year-over-year to $8.2 million; the TTM value through Sep 2025 reached $5.4 million, up 105.29%, while the annual FY2024 figure was $136000.0, 100.07% up from the prior year.
  • Profit After Tax for Q3 2025 was $8.2 million at Seres Therapeutics, up from -$19.9 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $88.8 million in Q3 2024 and bottomed at -$117.7 million in Q4 2023.
  • The 5-year median for Profit After Tax is -$35.5 million (2021), against an average of -$22.0 million.
  • The largest annual shift saw Profit After Tax skyrocketed 325.29% in 2021 before it crashed 5199.73% in 2023.
  • A 5-year view of Profit After Tax shows it stood at -$50.0 million in 2021, then surged by 95.56% to -$2.2 million in 2022, then plummeted by 5199.73% to -$117.7 million in 2023, then surged by 86.71% to -$15.6 million in 2024, then surged by 152.47% to $8.2 million in 2025.
  • Per Business Quant, the three most recent readings for MCRB's Profit After Tax are $8.2 million (Q3 2025), -$19.9 million (Q2 2025), and $32.7 million (Q1 2025).